OPT News

NYSE Content Advisory: Pre-Market Update + Optimum Communications to Ring Closing Bell

OPT

NEW YORK, Nov. 19, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on...

November 19, 2025
Read more →

Optiva Inc. Extends Forbearance Period with Noteholders to Continue Negotiations with Noteholders and Third Parties regarding a Potential Transaction

OPT

(NASDAQ:OPT) TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Further to its news release on July 18, 2025, Optiva Inc. (TSX: OPT) ("Optiva" or the "Company"), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today announced that it has entered into an amended support agreement dated September 3, 2025 with holders ("Noteholders") of approximately 85% of its outstanding principal amount of 9.75% senior secured PIK toggle notes due July 20, 2025 (the "Notes") providing for an extension of the grace period to allow Optiva's special committee of independent directors to conclude negotiations with Noteholders and prospective merger counterparties regarding a Potential Transaction (as defined below). The initial 45-day grace period, which was set to expire on September 3, 2025, has been extended to September 30, 2025 (the "Grace Period"). During the Grace Period, Noteholders who are parties to the support agreement ha

September 4, 2025Mergers
Read more →

Opthea Terminates Phase 3 Wet AMD Trials After ShORe Fails To Meet Primary Endpoint, Citing Lack Of Visual Benefit

OPT

March 31, 2025
Read more →

Leerink Partners Downgrades Opthea to Market Perform, Lowers Price Target to $1

OPT

March 25, 2025
Read more →

HC Wainwright & Co. Downgrades Opthea to Neutral, Lowers Price Target to $2

OPT

March 25, 2025
Read more →

Jefferies Downgrades Opthea to Underperform, Announces $1 Price Target

OPT

March 25, 2025
Read more →

Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty

OPT

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations.

March 24, 2025
Read more →

Opthea's Phase 3 COAST Trial Fails To Meet Primary Endpoint, Casting Doubt On Company's Future And Triggering Solvency Concerns

OPT

March 24, 2025
Read more →

Reported Earlier, Paratek Pharmaceuticals To Acquire Optinose In Deal Worth Up To $330M, Including $9 Cash And $5 In Milestone Cvrs Per Share

OPT

March 20, 2025
Read more →

Opthea Publishes Phase 2b Wet AMD Study In Peer-Reviewed Journal

OPT

March 3, 2025
Read more →

Opthea Half-Year Adjusted Non-IFRS Net Income $(69.8)M, Up From $(84.3)M YoY

OPT

February 28, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Opthea, Maintains $12 Price Target

OPT

February 28, 2025
Read more →